Hodgkin Dominic, Thomas Cindy Parks, O'Brien Peggy L, Levit Katharine, Richardson John, Mark Tami L, Malone Kevin
Heller School for Social Policy and Management, Brandeis University, Mailstop 35, Waltham, 02454, USA.
Behavioral Health and Quality Research, Truven Health Analytics, Cambridge, USA.
Adm Policy Ment Health. 2016 Jul;43(4):497-505. doi: 10.1007/s10488-015-0661-x.
Spending on psychotropic medications has grown rapidly in recent decades. Using national data on drug expenditures, patent expirations, future drug development and expert interviews, we project that spending will grow more slowly over the period 2012-2020. The average annual increase is projected to be just 3.0 % per year, continuing the steady deceleration in recent years. The main drivers of this expected deceleration include slower development of new drugs, upcoming patent expirations which will lower prices, and payers' growing ability to manage utilization and promote generic use. The slowdown will relieve some cost pressures on payers, particularly Medicare and Medicaid.
近几十年来,精神类药物的支出增长迅速。利用有关药品支出、专利到期、未来药物研发的全国数据以及专家访谈,我们预计在2012 - 2020年期间支出增长将放缓。预计年均增长率仅为3.0%,延续近年来的稳步减速态势。这种预期减速的主要驱动因素包括新药研发放缓、即将到期的专利将降低价格,以及支付方管理利用率和推广通用药物使用的能力不断增强。增长放缓将缓解支付方,尤其是医疗保险和医疗补助计划的一些成本压力。